Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.